Sudeep Pharma revenue climbs 28% as specialty ingredients take lead
The company reported annual revenue of ₹642.3 crore, though operational hurdles at its Nandesari plant and rising working capital remain key focus areas.
— 2 earlier stories on Sudeep Pharma Ltd. →What's new
- Specialty ingredients grew 62%, now accounting for 44% of total revenue.
- Working capital cycle stretched to 213 days due to inventory buildup.
- Nandesari greenfield facility faces commissioning delays from LPG shortages.
Why this matters
The shift toward specialty ingredients is paying off, but the company is paying for it in liquidity. A 213-day working capital cycle is a heavy burden that management must resolve to prove the business model is sustainable.
What we're watching
- Progress on the Dahej battery materials project ahead of its April 2027 start.
- Resolution of LPG shortages at the Nandesari facility.
- Any sign of working capital normalization in the coming quarters.
The full read
Sudeep Pharma closed FY26 with ₹642.3 crore in revenue, a 27.9% jump. The company's pivot toward specialty ingredients is the primary driver. That segment grew 62% over the year and now represents 44% of the company's total revenue, outpacing the core nutrition business. But the growth comes with operational friction. The Nandesari greenfield facility is behind schedule due to LPG shortages, and the company's working capital cycle has ballooned to 213 days following a strategic inventory spike. The Dahej battery materials project is the next test. Management expects a start in April 2027 and claims to have already secured 700 metric tons in orders from global customers looking for non-China supply chains. Whether the company can manage its liquidity while funding this expansion is the open question.
Questions answered
- What is driving Sudeep Pharma's revenue growth?
- Growth is led by the specialty ingredients vertical, which surged 62% this year and now makes up 44% of the company's total revenue.
- Why has the working capital cycle increased to 213 days?
- The increase is attributed to a temporary buildup of inventory levels, which management described as a strategic decision.
- What is the status of the Dahej battery materials project?
- The project remains on track for an April 2027 launch. The company has already locked in 700 metric tons of initial purchase orders from global clients.
- Are there any operational issues at the Nandesari plant?
- Yes, the greenfield facility is experiencing commissioning delays caused by fuel shortages, specifically LPG.
Story so far
All notes on SUDEEPPHRM →- 28 May 2026 · 2:08 PM IST Sudeep Pharma revenue climbs 28% as specialty ingredients take lead
- 7d ago Sudeep Pharma FY26: Revenue up 28%, PAT at ₹174 cr
- 7d ago Sudeep Pharma wraps FY26 with 28% revenue growth, 26% PAT jump